TY - JOUR
T1 - Anidulafungin
T2 - A drug evaluation of a new echinocandin
AU - Joseph, Jomy M.
AU - Kim, Rose
AU - Reboli, Annette C.
N1 - Funding Information:
A Reboli has received grant support from Merck and Pfizer, has been a consultant/adviser for Merck, Pfizer, Astellas and on the speakers bureau for Pfizer. R Kim was involved in a compassionate use study for Merck and has received an educational grant from Astellas Pharma US Inc.
Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2008/9
Y1 - 2008/9
N2 - Background: Over the past two decades, the frequency and type of invasive fungal infections have increased greatly and thus have driven the need for new antifungal agents. Anidulafungin is the newest addition to the echinocandin armamentarium. Objective: The intention of this review is to provide a drug evaluation of anidulafungin, including its spectrum of activity, pharmacokinetics, pharmacodynamics, clinical efficacy, adverse event profile, and its role in the treatment of invasive candidiasis. Methods: A PubMed search was performed to gather the most current and pertinent articles. Conclusions: Clinical trials have demonstrated anidulafungin's efficacy and tolerability in invasive candidiasis. Anidulafungin is not associated with any drug-drug interactions and does not require dosage adjustment in patients with renal and/or hepatic impairment.
AB - Background: Over the past two decades, the frequency and type of invasive fungal infections have increased greatly and thus have driven the need for new antifungal agents. Anidulafungin is the newest addition to the echinocandin armamentarium. Objective: The intention of this review is to provide a drug evaluation of anidulafungin, including its spectrum of activity, pharmacokinetics, pharmacodynamics, clinical efficacy, adverse event profile, and its role in the treatment of invasive candidiasis. Methods: A PubMed search was performed to gather the most current and pertinent articles. Conclusions: Clinical trials have demonstrated anidulafungin's efficacy and tolerability in invasive candidiasis. Anidulafungin is not associated with any drug-drug interactions and does not require dosage adjustment in patients with renal and/or hepatic impairment.
UR - http://www.scopus.com/inward/record.url?scp=52249114238&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=52249114238&partnerID=8YFLogxK
U2 - 10.1517/14656566.9.13.2339
DO - 10.1517/14656566.9.13.2339
M3 - Article
C2 - 18710358
AN - SCOPUS:52249114238
SN - 1465-6566
VL - 9
SP - 2339
EP - 2348
JO - Expert Opinion on Pharmacotherapy
JF - Expert Opinion on Pharmacotherapy
IS - 13
ER -